Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Inclusion Criteria: * Czech Republic: Age between 18 - 65 years (both inclusive) * A diagnosis of RA made at least 3 months prior to trial start * Active RA * Methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12 weeks with a stable dose for at least 4 weeks prior to trial start * Female subjects must be willing to avoid pregnancy and breast feeding throughout this trial at least until 15 weeks following the last dose of trial medication * Male subjects with partners of childbearing potential must be willing to use a highly effective contraception throughout trial incl. a 15 week follow up periode Exclusion Criteria: * Known or suspected allergy to trial product or related products * Body Mass Index (BMI) lower than 18.5 or higher than 35.0 kg/m\^2 * Subjects with chronic inflammatory autoimmune disease other than RA (except secondary Sjögren's syndrome or stable hypothyroidism)